Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT03817424 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03817424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03817424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2018
Completion date
July 20, 2020
Enrollment
31 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus, dermatomyositis, polymyositis, sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis